Illumina, Inc. $ILMN Stock Position Reduced by Crossmark Global Holdings Inc.

Key Points

• Crossmark Global Holdings cut its Illumina position by 67.7% in the third quarter, selling 11,546 shares and retaining 5,513 shares worth approximately $1.51 million. Institutional investors collectively own 89.42% of the company.
• Illumina insiders sold 2.06 million shares worth approximately $436.5 million over the past 90 days, including a $26.1 million sale by director Keith Meister.
• Illumina’s latest quarterly results exceeded expectations, with EPS of $1.31 and revenue of $1.16 billion, while analysts maintain a consensus “Hold” rating and an average price target of $234.41.

Crossmark Global Holdings Inc. lowered its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 67.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,513 shares of the life sciences company's stock after selling 11,546 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Illumina were worth $1,509,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in ILMN. Quadrant Capital Group LLC lifted its stake in shares of Illumina by 3.2% during the 3rd quarter. Quadrant Capital Group LLC now owns 20,702 shares of the life sciences company's stock valued at $5,614,000 after buying an additional 640 shares in the last quarter. Pinnacle Associates Ltd. increased its stake in Illumina by 2.2% in the 3rd quarter. Pinnacle Associates Ltd. now owns 2,506 shares of the life sciences company's stock worth $686,000 after buying an additional 54 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Illumina by 52.5% during the third quarter. Robeco Institutional Asset Management B.V. now owns 469,340 shares of the life sciences company's stock valued at $128,449,000 after acquiring an additional 161,555 shares during the period. LCM Capital Management Inc bought a new stake in Illumina during the third quarter valued at about $280,000. Finally, Prime Capital Investment Advisors LLC bought a new stake in Illumina during the third quarter valued at about $250,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Insider Buying and Selling

In other news, SVP Christensen Wedel sold 1,033 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president directly owned 14,023 shares of the company's stock, valued at $2,685,684.96. This represents a 6.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total value of $26,099,018.40. Following the transaction, the director owned 770,350 shares of the company's stock, valued at $168,244,440. This represents a 13.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 2,061,850 shares of company stock worth $436,479,102. Corporate insiders own 2.90% of the company's stock.

Illumina Stock Performance

Shares of Illumina stock opened at $269.42 on Monday. The firm has a market cap of $40.68 billion, a price-to-earnings ratio of 50.26, a PEG ratio of 3.82 and a beta of 1.41. The business has a 50-day moving average price of $242.35 and a 200-day moving average price of $191.54. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a twelve month low of $94.00 and a twelve month high of $309.35.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%. The business's revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina’s upcoming quarterly report could benefit from strong clinical demand, NovaSeq X adoption, new instrument placements, and consumables growth. Analysts also expect year-over-year earnings growth and see potential for an earnings beat, although research-market weakness remains a concern. ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
• Positive Sentiment: The company launched three early-access capabilities for its BioInsight Platform—Workflow Orchestrator, DRAGEN Ultra with dnaAI, and Learning Cohorts. The tools expand Illumina’s AI-driven variant prioritization, sequencing analysis, and genomic-data workflow offerings, potentially increasing the strategic importance of software and data services. How Investors May Respond To Illumina BioInsight AI Rollout
• Neutral Sentiment: Illumina is expected to report quarterly results next week. The event is a major near-term catalyst, with investor attention likely centered on clinical demand, NovaSeq X placements, consumables revenue, and management’s outlook. Illumina Expected to Release Quarterly Earnings on Thursday
• Neutral Sentiment: The consensus price target was raised 19.65% to $250.77, signaling improved analyst expectations, but that target remains below Illumina’s recent trading level and may limit upside if not revised further. Illumina Consensus Price Target Increased
• Negative Sentiment: Stephens downgraded Illumina to Equal Weight, reducing a potential source of buying pressure and reflecting a more cautious view of the stock’s risk-reward profile. Stephens Downgrades Illumina to Equal Weight
• Negative Sentiment: Illumina recently fell alongside Twist Bioscience and other AI- and genomics-related stocks in a broad technology selloff, indicating that sector sentiment—not company-specific news—has also been driving volatility. Twist Bioscience and Illumina Slide as AI and Genomics Stocks Sell Off

Analyst Ratings Changes

Several equities analysts have recently commented on the company. UBS Group upgraded Illumina from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $135.00 to $260.00 in a research report on Wednesday, September 9th. Guggenheim increased their target price on Illumina from $226.00 to $305.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. Citigroup lifted their target price on Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a research note on Monday, August 3rd. Leerink Partners boosted their price target on Illumina from $220.00 to $300.00 and gave the stock an "outperform" rating in a report on Tuesday, September 29th. Finally, Stephens restated an "equal weight" rating and issued a $275.00 price target on shares of Illumina in a research note on Friday. Ten analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $234.41.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.